Skip to content

Vitamin D Supplementation and Glycemic Outcomes

Effect of Treating Vitamin D Deficiency on Glucose Homeostasis and Metabolic Markers in Apparently Healthy, Young or Aged, Normal-weight or Obese Lebanese People

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02942732
Enrollment
180
Registered
2016-10-24
Start date
2013-02-28
Completion date
2013-12-31
Last updated
2016-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance

Keywords

Vitamin D, Glucose, HbA1C, Insulin resistance, Blood lipids

Brief summary

The investigators examined the effect of vitamin D supplementation on glucose homeostasis and metabolic markers in healthy normal weight and overweight young subjects and healthy normal-weight and overweight elderly subjects living in Beirut, Lebanon.

Detailed description

A low serum 25-hydroxyvitamin D (25(OH)D) concentration has been shown to correlate with higher fasting blood glucose (FBG) and insulin levels and other metabolic abnormalities like dyslipidemia. Previous studies suggest that vitamin D supplementation is able to improve insulin sensitivity and metabolic markers. The aim of the study was to investigate the effect of vitamin D supplementation on glucose homeostasis and metabolic markers in healthy normal weight and overweight young subjects and healthy normal-weight and overweight elderly subjects living in Beirut, Lebanon. Participants (n= 180; 93 men and 87 women) deficient in vitamin D were recruited from Saint Charles Hospital, Beirut, Lebanon. Four groups were recruited: normal-weight adults (n=30, age ≤ 65 years and BMI \< 25 kg/m²), overweight adults (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²), normal-weight elderly (n=60, age ≥ 65 years and BMI \< 25 kg/m²) and overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²). Participants received a supplement of 10,000 IU cholecalciferol to be taken three times per week for a period of 6 months. Glucose homeostasis and metabolic markers were measured at start of treatment, at 3 months and at 6 months.

Interventions

All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.

Sponsors

Université d'Auvergne
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants with no medical history of congestive heart failure, acute heart insufficiency and renal failure were included

Exclusion criteria

* Participants with medical history of congestive heart failure, acute heart insufficiency and renal failure were excluded

Design outcomes

Primary

MeasureTime frameDescription
Fasting blood glucose (mmol/l)Baseline and 6 monthsChange in Fasting blood glucose in mmol/l
HbA1C (%)Baseline and 6 monthsChange in HbA1C (%)
HOMA-IRBaseline and 6 monthsChange in HOMA-IR
Fasting Insulin (mIU/L)Baseline and 6 monthsChange in Fasting Insulin (mIU/L)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026